Parkinson disease: Protective role and function of neuropeptides

Tabikh, Mireille; Chahla, C.; Okdeh, Nathalie; Kovacic, Hervé; Sabatier, Jean‐Marc; Fajloun, Ziad

doi:10.1016/j.peptides.2021.170713

Cited by 8 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After evaluating the neuroprotective effects of PACAP on 2D SH-SY5Y/RA, we produced 3D SH-SY5Y/RA cells by hanging drop method (2 × 10 4 cells per aggregate) [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ]. After 48 h from the aggregate’s formation, they were transferred in an LB1 bioreactor.…”

Section: Methodsmentioning

confidence: 99%

“…The 3D SH-SY5Y/RA/MPP + and 3D SH-SY5Y/RA were adapted to flow condition in two LB1s for 24 h. Once adapted, they were transferred in the lower chamber of three LB2s. LB2 is a double chamber (upper and lower) bioreactor with double independent inlet and outlet tube used to mimic physiological barrier [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ]. The double chambers are separated by a porous membrane (0.45 µm, ipPORE, Belgium).…”

Section: Methodsmentioning

confidence: 99%

“…Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuroprotective peptide that acts in many exogenous stimuli [ 25 ]. It is a polypeptide of 27–38 amino acids, conserved of the superfamily secretin/PACAP/glucagon, of which it belongs, for length and nucleotide sequence [ 26 ], which shows a particularly high homology with the intestinal peptide vasoactive (VIP). The neuroprotective action takes place through anti-inflammatory pathways [ 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson’s Disease

et al. 2022

View full text Add to dashboard Cite

Parkinson’s disease (PD) is an aggressive and devastating age-related disorder. Although the causes are still unclear, several factors, including genetic and environmental, are involved. Except for symptomatic drugs, there are not, to date, any real cures for PD. For this purpose, it is necessary develop a model to better study this disease. Neuroblastoma cell line, SH-SY5Y, differentiated with retinoic acid represents a good in vitro model to explore PD, since it maintains growth cells to differentiated neurons. In the present study, SH-SY5Y cells were treated with 1-methyl-4-phenylpyridinium (MPP+), a neurotoxin that induces Parkinsonism, and the neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP), delivered by functionalized liposomes in a blood–brain barrier fluid dynamic model, were evaluated. We demonstrated PACAP neuroprotective effects when delivered by gH625-liposome on MPP+-damaged SH-SY5Y spheroids.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson’s Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The Ang II/AT 1 R axis has inhibitory effects on GABA and excitatory effects on glutamate. Thus, it is suggested that activating type 1 receptors plays an important role in motor deficits in PD through the indirect pathway of the SN [ 56 ]. Large studies suggest that using RAS inhibitors may be associated with a reduced risk of PD.…”

Section: Renin-angiotensin-aldosterone System and Parkinson’s Diseasementioning

confidence: 99%

Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases

et al. 2022

View full text Add to dashboard Cite

Brain neurodegenerative diseases (BND) are debilitating conditions that are especially characteristic of a certain period of life and considered major threats to human health. Current treatments are limited, meaning that there is a challenge in developing new options that can efficiently tackle the different components and pathophysiological processes of these conditions. The renin-angiotensin-aldosterone system (RAS) is an endocrine axis with important peripheral physiological functions such as blood pressure and cardiovascular homeostasis, as well as water and sodium balance and systemic vascular resistance—functions which are well-documented. However, recent work has highlighted the paracrine and autocrine functions of RAS in different tissues, including the central nervous system (CNS). It is known that RAS hyperactivation has pro-inflammatory and pro-oxidant effects, thus suggesting that its pharmacological modulation could be used in the management of these conditions. The present paper underlines the involvement of RAS and its components in the pathophysiology of BNDs such as Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS), Huntington’s disease (HD), motor neuron disease (MND), and prion disease (PRD), as well as the identification of drugs and pharmacologically active substances that act upon RAS, which could alleviate their symptomatology or evolution, and thus, contribute to novel therapeutic approaches.

show abstract

“…(PD) pathology and include: the regulation of sleep-wake states, regulation of motor control, eating behavior, respiratory function, gastric motility, reward systems, mood, anxiety, stress, neuroprotection, learning, memory, and pain regulation (Date et al, 1999;Ehrström et al, 2005;Hu et al, 2015;Oliveira et al, 2020;Razavi & Hosseinzadeh, 2017;Sakurai et al, 1998;Tabikh et al, 2021).…”

mentioning

confidence: 99%

The role of orexin in Parkinson's disease

Braun,

Manavis,

Yamanaka

et al. 2024

J of Neuroscience Research

View full text Add to dashboard Cite

Emerging evidence has implicated the orexin system in non‐motor pathogenesis of Parkinson's disease. It has also been suggested the orexin system is involved in the modulation of motor control, further implicating the orexin system in Parkinson's disease. Parkinson's disease is the second most common neurodegenerative disease with millions of people suffering worldwide with motor and non‐motor symptoms, significantly affecting their quality of life. Treatments are based solely on symptomatic management and no cure currently exists. The orexin system has the potential to be a treatment target in Parkinson's disease, particularly in the non‐motor stage. In this review, the most current evidence on the orexin system in Parkinson's disease and its potential role in motor and non‐motor symptoms of the disease is summarized. This review begins with a brief overview of Parkinson's disease, animal models of the disease, and the orexin system. This leads into discussion of the possible roles of orexin neurons in Parkinson's disease and levels of orexin in the cerebral spinal fluid and plasma in Parkinson's disease and animal models of the disease. The role of orexin is then discussed in relation to symptoms of the disease including motor control, sleep, cognitive impairment, psychological behaviors, and the gastrointestinal system. The neuroprotective effects of orexin are also summarized in preclinical models of the disease.

show abstract

Parkinson disease: Protective role and function of neuropeptides

Cited by 8 publications

References 106 publications

Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson’s Disease

Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson’s Disease

Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases

The role of orexin in Parkinson's disease

Contact Info

Product

Resources

About